Emerging Treatments in Schizophrenia: Highlights from Recent Supplementation and Prevention Trials

Harvard Review of Psychiatry

Volumn 24, Issue 2, 2016, Pages e1-e7

  Brown, Hannah E ^a   Roffman, Joshua L ^a   Wood, Julia K ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE   (United States)

Author keywords

adjunctive antipsychotic treatment; glutamatergic agents; schizophrenia; vitamin supplementation

Indexed keywords

ALPHA TOCOPHEROL; ANTIINFLAMMATORY AGENT; ASCORBIC ACID; BENZOIC ACID; BEXAROTENE; GLYCINE; MEMANTINE; MINOCYCLINE; NEUROLEPTIC AGENT; NITROPRUSSIDE SODIUM; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; ONDANSETRON; PRAVASTATIN; SIMVASTATIN; VITAMIN B GROUP; VITAMIN D; AMINO ACID RECEPTOR AFFECTING AGENT; VITAMIN;

ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); GLUTAMATERGIC SYNAPSE; HUMAN; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SUPPLEMENTATION; COMBINATION DRUG THERAPY; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; ANTIPSYCHOTIC AGENTS; DRUG THERAPY, COMBINATION; EXCITATORY AMINO ACID AGENTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; TREATMENT OUTCOME; VITAMINS;

EID: 84962521922     PISSN: 10673229     EISSN: 14657309     Source Type: Journal    
DOI: 10.1097/HRP.0000000000000101     Document Type: Article

References (61)

1. Balu DT, Coyle JT,. The NMDA receptor glycine modulatory site in schizophrenia: D-serine, glycine, and beyond. Curr Opin Pharmacol 2015; 20: 109-15.
2. Krystal JH, Karper LP, Seibyl JP,. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51: 199-214.
3. Buchanan RW, Javitt DC, Marder SR,. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 2007; 164: 1593-602.
4. Goff DC, Cather C, Gottlieb JD,. Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study. Schizophr Res 2008; 106: 320-7.
5. Goff DC,. D-cycloserine: an evolving role in learning and neuroplasticity in schizophrenia. Schizophr Bull 2012; 38: 936-41.
6. Tsai G, Lane HY, Yang P, Chong MY, Lange N,. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2004; 55: 452-6.
7. Umbricht D, Alberati D, Martin-Facklam M,. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study. JAMA Psychiatry 2014; 71: 637-46.
8. Lane HY, Lin CH, Green MF,. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. JAMA Psychiatry 2013; 70: 1267-75.
9. Hallak JE, Maia-de-Oliveira JP, Abrao J,. Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial. JAMA Psychiatry 2013; 70: 668-76.
10. Zdanys K, Tampi RR,. A systematic review of off-label uses of memantine for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1362-74.
11. Krivoy A, Weizman A, Laor L, Hellinger N, Zemishlany Z, Fischel T,. Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: a preliminary study. Eur Neuropsychopharmacol 2008; 18: 117-21.
12. de Lucena D, Fernandes BS, Berk M,. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. J Clin Psychiatry 2009; 70: 1416-23.
13. Rezaei F, Mohammad-Karimi M, Seddighi S,. Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2013; 33: 336-42.
14. Lieberman JA, Papadakis K, Csernansky J,. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology 2009; 34: 1322-9.
15. Monji A, Kato TA, Mizoguchi Y,. Neuroinflammation in schizophrenia especially focused on the role of microglia. Prog Neuropsychopharmacol Biol Psychiatry 2013; 42: 115-21.
16. Smith RS, Maes M,. The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Med Hypotheses 1995; 45: 135-41.
17. Garcia-Bueno B, Bioque M, Mac-Dowell KS,. Pro-/anti-inflammatory dysregulation in patients with first episode of psychosis: toward an integrative inflammatory hypothesis of schizophrenia. Schizophr Bull 2014; 40: 376-87.
18. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B,. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011; 70: 663-71.
19. van Berckel BN, Bossong MG, Boellaard R,. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry 2008; 64: 820-2.
20. Kirkpatrick B, Miller BJ,. Inflammation and schizophrenia. Schizophr Bull 2013; 39: 1174-9.
21. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014; 511: 421-7.
22. Laan W, Grobbee DE, Selten JP, Heijnen CJ, Kahn RS, Burger H,. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2010; 71: 520-7.
23. Muller N, Riedel M, Scheppach C,. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 2002; 159: 1029-34.
24. Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B,. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res 2007; 90: 179-85.
25. Rapaport MH, Delrahim KK, Bresee CJ, Maddux RE, Ahmadpour O, Dolnak D,. Celecoxib augmentation of continuously ill patients with schizophrenia. Biol Psychiatry 2005; 57: 1594-6.
26. Muller N, Krause D, Dehning S,. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res 2010; 121: 118-24.
27. Glantz LA, Gilmore JH, Lieberman JA, Jarskog LF,. Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophr Res 2006; 81: 47-63.
28. Chaudhry IB, Hallak J, Husain N,. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol 2012; 26: 1185-93.
29. Liu F, Guo X, Wu R,. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial. Schizophr Res 2014; 153: 169-76.
30. Akhondzadeh S, Mohammadi N, Noroozian M,. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial. Schizophr Res 2009; 107: 206-12.
31. Chaudhry IB, Husain N, Drake R,. Add-on clinical effects of simvastatin and ondansetron in patients with schizophrenia stabilized on antipsychotic treatment: pilot study. Ther Adv Psychopharmacol 2014; 4: 110-6.
32. Vincenzi B, Stock S, Borba CP,. A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism. Schizophr Res 2014; 159: 395-403.
33. Muntjewerff JW, van der Put N, Eskes T,. Homocysteine metabolism and B-vitamins in schizophrenic patients: low plasma folate as a possible independent risk factor for schizophrenia. Psychiatry Res 2003; 121: 1-9.
34. Kale A, Naphade N, Sapkale S,. Reduced folic acid, vitamin B12 and docosahexaenoic acid and increased homocysteine and cortisol in never-medicated schizophrenia patients: implications for altered one-carbon metabolism. Psychiatry Res 2010; 175: 47-53.
35. Gracious BL, Finucane TL, Friedman-Campbell M, Messing S, Parkhurst MN,. Vitamin D deficiency and psychotic features in mentally ill adolescents: a cross-sectional study. BMC Psychiatry 2012; 12: 38.
36. Belvederi Murri M, Respino M, Masotti M,. Vitamin D and psychosis: mini meta-analysis. Schizophr Res 2013; 150: 235-9.
37. McGrath JJ, Eyles DW, Pedersen CB,. Neonatal vitamin D status and risk of schizophrenia: a population-based case-control study. Arch Gen Psychiatry 2010; 67: 889-94.
38. Susser E, Neugebauer R, Hoek HW,. Schizophrenia after prenatal famine. Further evidence. Arch Gen Psychiatry 1996; 53: 25-31.
39. Kemperman RF, Veurink M, van der Wal T,. Low essential fatty acid and B-vitamin status in a subgroup of patients with schizophrenia and its response to dietary supplementation. Prostaglandins Leukot Essent Fatty Acids 2006; 74: 75-85.
40. Goff DC, Bottiglieri T, Arning E,. Folate, homocysteine, and negative symptoms in schizophrenia. Am J Psychiatry 2004; 161: 1705-8.
41. Roffman JL, Lamberti JS, Achtyes E,. Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia. JAMA Psychiatry 2013; 70: 481-9.
42. Hill M, Shannahan K, Jasinski S,. Folate supplementation in schizophrenia: a possible role for MTHFR genotype. Schizophr Res 2011; 127: 41-5.
43. Menkes DB, Lancaster K, Grant M, Marsh RW, Dean P, du Toit SA,. Vitamin D status of psychiatric inpatients in New Zealands Waikato region. BMC Psychiatry 2012; 12: 68.
44. Crews M, Lally J, Gardner-Sood P,. Vitamin D deficiency in first episode psychosis: a case-control study. Schizophr Res 2013; 150: 533-7.
45. McGrath J, Saari K, Hakko H,. Vitamin D supplementation during the first year of life and risk of schizophrenia: a Finnish birth cohort study. Schizophr Res 2004; 67: 237-45.
46. Dealberto MJ,. Clinical symptoms of psychotic episodes and 25-hydroxy vitamin D serum levels in black first-generation immigrants. Acta Psychiatr Scand 2013; 128: 475-87.
47. Suboticanec K, Folnegovic-Smalc V, Turcin R, Mestrovic B, Buzina R,. Plasma levels and urinary vitamin C excretion in schizophrenic patients. Hum Nutr Clin Nutr 1986; 40: 421-8.
48. DSouza B, DSouza V,. Oxidative injury and antioxidant vitamins E and C in schizophrenia. Indian J Clin Biochem 2003; 18: 87-90.
49. Bentsen H, Osnes K, Refsum H, Solberg DK, Bohmer T,. A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E + C in schizophrenia. Transl Psychiatry 2013; 3: e335.
50. Dakhale GN, Khanzode SD, Khanzode SS, Saoji A,. Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. Psychopharmacology (Berl) 2005; 182: 494-8.
51. Goodman AB,. Microarray results suggest altered transport and lowered synthesis of retinoic acid in schizophrenia. Mol Psychiatry 2005; 10: 620-1.
52. Rioux L, Arnold SE,. The expression of retinoic acid receptor alpha is increased in the granule cells of the dentate gyrus in schizophrenia. Psychiatry Res 2005; 133: 13-21.
53. Lerner V, Miodownik C, Gibel A,. The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial. J Clin Psychiatry 2013; 74: 1224-32.
54. Horrobin DF, Manku MS, Hillman H, Iain A, Glen M,. Fatty acid levels in the brains of schizophrenics and normal controls. Biol Psychiatry 1991; 30: 795-805.
55. Peet M, Laugharne J, Rangarajan N, Horrobin D, Reynolds G,. Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. J Psychiatr Res 1995; 29: 227-32.
56. Mahadik SP, Mukherjee S, Horrobin DF, Jenkins K, Correnti EE, Scheffer RE,. Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar patients and normal subjects. Psychiatry Res 1996; 63: 133-42.
57. Horrobin DF,. Schizophrenia as a membrane lipid disorder which is expressed throughout the body. Prostaglandins Leukot Essent Fatty Acids 1996; 55: 3-7.
58. Emsley R, Myburgh C, Oosthuizen P, van Rensburg SJ,. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry 2002; 159: 1596-8.
59. Fenton WS, Dickerson F, Boronow J, Hibbeln JR, Knable M,. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 2001; 158: 2071-4.
60. Emsley R, Chiliza B, Asmal L,. A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia. Schizophr Res 2014; 158: 230-5.
61. Amminger GP, Schafer MR, Papageorgiou K,. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2010; 67: 146-54.